KCIA
XBI icon

Kingsbury Capital Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,248
Closed -$831K – 105
2022
Q1 		$831K Buy
+9,248
New +$854K 0.91% 24

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Kingsbury Capital Investment Advisors's XBI Position: Q2 2022 in Review

Kingsbury Capital Investment Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 9,248 shares — an estimated $831K sold.

Kingsbury Capital Investment Advisors first reported a position in XBI in Q1 2022 and held it in 1 quarter. The position peaked at $831K in Q1 2022. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

  • Kingsbury Capital Investment Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • Kingsbury Capital Investment Advisors sold 9,248 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $831K.
  • Kingsbury Capital Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 1 quarter.
  • Kingsbury Capital Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $831K in Q1 2022.
  • 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.